What is the Pulmonary Rehabilitation Adapted Index of Self-Efficacy tool actually measuring?

www.chestpubs.org aminophylline for status asthmaticus in the PICU (e-Appendix 1 ). The survey was distributed three times at 3-week intervals, and responses were anonymous. The study protocol and questionnaire were approved by the Vanderbilt University institutional review board (protocol No. 101136). Responses were received from 39 of the surveyed program directors (67%). Twenty-three of those responses (59%) indicated that their PICUs currently use aminophylline for status asthmaticus. All positive respondents (100%) indicated that aminophylline use was based on clinical judgment rather than institutional protocol. Twenty of those using aminophylline (87%) stated that the medication was used only when other treatments had failed. Fourteen of the respondents (61%) whose institution used aminophylline identifi ed a therapeutic range for serum aminophylline levels. Six of these respondents (43%) identifi ed a therapeutic serum level of 10 to 20 m g/mL for aminophylline, the generally accepted therapeutic range. 4 There was variation in the reporting of both the minimal effective serum level (mean, 10 m g/mL; range, 5-15 m g/mL) and the toxic serum level (mean, 17.9 m g/mL; range, 10-25 m g/mL ). Aminophylline continues to be used to treat status asthmaticus in PICUs, as determined by surveying fellowship training programs, despite limited evidence for effi cacy and expert guidelines recommending against its use for this purpose. If pediatric critical care physicians are to continue to use this drug, further studies are recommended and warranted to assess its effi cacy and safety.